Short answer
SOLENO THERAPEUTICS INC (SLNO) filed an 8-K current report with the SEC on May 18, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Merger completed May 18, 2026 under DGCL Section 251(h), without a stockholder vote.
SOLENO THERAPEUTICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Merger completed May 18, 2026 under DGCL Section 251(h), without a stockholder vote
- Soleno became a direct wholly owned subsidiary of Parent
- Acquisition completion ends Soleno’s standalone public-company status and shifts control to Parent
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Merger consummated, triggering Nasdaq delisting of Soleno shares
- Form 25 requested to remove Shares from Nasdaq and terminate Section 12(b) registration
- Form 15 planned to suspend SEC reporting obligations under Sections 13 and 15(d)
- Public-market trading and ongoing disclosure expected to end following delisting നടപട
Item 3.03 · Material Modification to Rights of Security Holders
- Merger completion triggered a control change, making Soleno a direct wholly owned subsidiary of Parent
- Offer consideration funded with Parent’s cash on hand, indicating no disclosed acquisition financing
- Public shareholders’ ownership rights ended or were materially altered through the completed merger and offer process
Item 5.01 · Changes in Control of Registrant
- Introductory Note contains the substantive change-in-control details
- Control-change implications cannot be assessed from this excerpt alone
Item 5.02 · Departure/Election of Directors or Officers
- Eight senior officers, including CEO Anish Bhatnagar and CFO Jennifer Fulk, resigned effective upon merger closing
- Matthew C. Abernethy and Darin M. Lippoldt replaced the board, becoming the company’s only directors
- Post-merger leadership concentrated in Abernethy as Treasurer/Vice President and Lippoldt as President/Secretary
- Departures tied to the merger, not reported disagreements over operations, policies, or practices
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Certificate of incorporation and bylaws amended and restated in full at merger closing
- Changes implement the Merger Agreement and may reset governance provisions and shareholder rights
- Investors should review Exhibits 3.1 and 3.2 for voting, board, indemnification, and procedural changes
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SOLENO THERAPEUTICS INC 8-K filings
Get the next SLNO 8-K as it lands
Follow SLNO for push alerts, or ask the research agent what this filing means.